- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET mammography reduces unnecessary biopsies
Positron-emission mammography may reduce unnecessary breast biopsies, according to data from an NIH-sponsored multisite study. Devices were provided by Naviscan.
Positron-emission mammography may reduce unnecessary breast biopsies, according to data from an NIH-sponsored multisite study. Devices were provided by Naviscan. PEM demonstrated a 6% improvement in specificity compared with breast MR, according to the research. PEM also led to 31 fewer unnecessary biopsies and a 26% higher positive predicative value compared with breast MR.
“The results of this study mean not only do physicians have an additional, powerful tool to help treat breast cancer, but that PEM is a better alternative for the 16% of women who cannot tolerate MR due to claustrophobia, metallic implants, body habitus, or gadolinium reaction,” said Dr. Wendie Berg, principal investigator for the trial and breast imaging specialist at Johns Hopkins Health Care and Surgery Center at Green Spring Station in Lutherville, MD.
The trial examined women from six locations who had newly diagnosed breast cancer. Officials for Naviscan said they have submitted the manuscript to Radiology and anticipate a response by the end of April.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
